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A B S T R A C T
Purpose
The relative value of gemcitabine-based combination chemotherapy therapy and prolonged
infusions of gemcitabine in patients with advanced pancreatic cancer remains controversial. We
explored the efficacy and toxicity of gemcitabine administered at a fixed dose rate or in combination
with cisplatin, docetaxel, or irinotecan in a multi-institutional, randomized, phase II study.
Patients and Methods
Patients with metastatic pancreatic cancer were randomly assigned to one of the following four
regimens: gemcitabine 1,000 mg/m2 on days 1, 8, and 15 with cisplatin 50 mg/m2 on days 1 and 15 (arm
A); gemcitabine 1,500 mg/m2 at a rate of 10 mg/m2/min on days 1, 8, and 15 (arm B); gemcitabine 1,000
mg/m2 with docetaxel 40 mg/m2 on days 1 and 8 (arm C); or gemcitabine 1,000 mg/m2 with irinotecan 100
mg/m2 on days 1 and 8 (arm D). Patients were observed for response, toxicity, and survival.
Results
Two hundred fifty-nine patients were enrolled onto the study, of whom 245 were eligible and
received treatment. Anticipated rates of myelosuppression, fatigue, and expected regimen-
specific toxicities were observed. The overall tumor response rates were 12% to 14%, and the
median overall survival times were 6.4 to 7.1 months among the four regimens.
Conclusion
Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and gemcitabine/
irinotecan have similar antitumor activity in metastatic pancreatic cancer. In light of recent negative
randomized studies directly comparing several of these regimens with standard gemcitabine,
none of these approaches can be recommended for routine use in patients with this disease.
J Clin Oncol 27:5506-5512. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Pancreatic adenocarcinoma is resistant to many
systemic therapies and continues to be a leading
cause of cancer-related death.1 The administration
of single-agent gemcitabine has been a mainstay of
pancreatic cancer treatment based on evidence of
clinical benefit and prolongation of survival when
compared with fluorouracil in patients with ad-
vanced disease.2 However, objective tumor re-
sponses after treatment with gemcitabine occur in
less than 10% of patients, and median survival times
are usually less than 6 months.
Combining gemcitabine with a second sys-
temic agent has seemed to be a logical way to poten-
tially enhance response rates and survival times for
patients with advanced pancreatic cancer. This ap-
proach has unfortunately met with only limited suc-
cess. A combination of gemcitabine and erlotinib
was associated with a modest improvement in sur-
vival (hazard ratio for death  0.82; P  .038) when
compared with gemcitabine alone. However, the ad-
dition of the erlotinib was also associated with a
higher incidence of rash, diarrhea, and hematologic
toxicity.3 In the preliminary report of a randomized
study comparing gemcitabine and capecitabine with
gemcitabine alone in 533 patients, the gemcitabine/
capecitabine combination was associated with an
enhanced overall response rate (14.2% v 7.1%, re-
spectively) and a modest improvement in median
survival time (7.4 v 6 months, respectively).4 The
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final report of a similar study, however, failed to demonstrate a signif-
icant survival advantage in the capecitabine-containing arm.5
Both irinotecan and docetaxel have been reported to have mod-
est single-agent activity in pancreatic cancer.6-8 Single-arm studies
combining either of these agents with gemcitabine demonstrated their
safety and showed preliminary evidence of promising activity.9,10 Sim-
ilarly, the combination of gemcitabine and cisplatin was associated
with encouraging antitumor activity, with a reported overall response
rate of 11% in a phase II study comprising 41 pancreatic cancer
patients.11 A fourth approach, modulating gemcitabine by adminis-
tration at a fixed dose rate, was developed as an alternative technique
to potentially increase the efficacy of gemcitabine.12 After intravenous
administration, gemcitabine undergoes intracellular phosphorylation
to its active triphosphate metabolite, 2,2-difluoro 2-deoxycytidine
triphosphate.13 The rate of formation of this metabolite is dose rate
dependent and can be increased through the use of prolonged infu-
sions, thereby enhancing its cytotoxic effect.
To further evaluate the efficacy and toxicity of gemcitabine-based
chemotherapy regimens in pancreatic cancer, we performed a ran-
domized phase II study of three different gemcitabine-based combi-
nations or fixed dose rate infusion gemcitabine in patients with
advanced pancreatic cancer, with the goal of identifying a promising
regimen to take forward into a formal phase III study. Two hundred
fifty-nine patients were randomly assigned to receive either gemcitab-
ine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, or
gemcitabine/irinotecan. Patients were observed for the primary end
point of overall survival (OS) at 6 months. Secondary end points
included toxicity, radiologic response, biochemical (CA 19-9) re-
sponse, and time to tumor progression (TTP).
PATIENTS AND METHODS
Patient Characteristics
Eligible patients for this study were required to have biopsy-documented
pancreatic adenocarcinoma, with evidence of distant metastatic disease. Pa-
tients with locally advanced disease without metastases were not eligible. Prior
adjuvant therapy with fluorouracil and/or radiation therapy was allowed if
such treatment had been completed at least 2 weeks before registration. All
patients were age  18 years and had Eastern Cooperative Oncology Group
(ECOG) performance status of 0 to 2, adequate hematologic function, creati-
nine  1.5 mg/dL, total bilirubin  1.5 mg/dL, AST  2.5 upper limit of
normal (ULN), and alkaline phosphatase  2.5 ULN if AST was more than
1.5 ULN (alkaline phosphatase of any value was accepted if AST  1.5
ULN). This protocol was reviewed by the institutional review board of each
participating center, and all patients provided written informed consent before
participation in the study.
Trial Structure and Organization
Patient registration and data collection were managed by the Cancer and
Leukemia Group B (CALGB) Statistical Center. Data quality was ensured by
careful review of data by CALGB Statistical Center staff and by the study chair.
All analyses were performed by CALGB statisticians based on the study data-
base frozen on March 11, 2008.
Treatment Plan
Patients were randomly assigned to receive one of the following four
regimens: gemcitabine/cisplatin (arm A), fixed dose rate gemcitabine (arm B),
gemcitabine/docetaxel (arm C), or gemcitabine/irinotecan (arm D). Initial
dosing regimens were as follows. In arm A, gemcitabine was administered as a
30-minute infusion at a dose of 1,000 mg/m2 on days, 1, 8, and 15, every 28
days. Cisplatin was administered over 30 minutes at a dose of 50 mg/m2 on
days 1 and 15, every 28 days. In arm B, gemcitabine was administered at a dose
of 1,500 mg/m2 at a rate of 10 mg/m2/min on days 1, 8, and 15, every 28 days.
























Patients enrolled 66 64 65 64 259
Patients treated 62 58 65 60 245
Age, years
Median 58.9 58.9 62.9 60.8 60.5
Range 36-84 31-81 41-79 32-77 31-84
Sex
Male 35 56 38 66 40 62 41 68 154 63
Female 27 44 20 34 25 38 19 32 91 37
Performance status
0 15 24 14 24 22 34 23 39 74 30
1 40 65 36 62 36 55 31 53 143 59
2 7 11 8 14 7 11 5 8 27 11
Prior treatment with FU
No 58 94 49 84 58 89 51 86 216 89
Yes 4 6 9 16 7 11 8 14 28 11
Prior treatment with radiation therapy
No 56 90 47 81 57 88 51 86 211 86
Yes 6 10 11 19 8 12 8 14 33 14
Median weeks on study treatment 9.6 6.1 8.4 12.1 9.0
Required dose modifications or delays 58 94 45 78 46 71 49 83 198 81
Received second-line treatment after study 21 34 15 26 21 32 15 25 72 30
Abbreviations: FDR, fixed dose rate; FU, fluorouracil.
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In arm C, gemcitabine was administered as a 30-minute infusion at a dose of
1,000 mg/m2 on days 1 and 8, every 21 days. Docetaxel was administered
immediately after gemcitabine at a dose of 40 mg/m2 on days 1 and 8. Premed-
ication with dexamethasone was recommended. In arm D, gemcitabine was
administered as a 30-minute infusion at a dose of 1,000 mg/m2 on days 1 and
8, every 21 days. Irinotecan was administered immediately after gemcitabine at
a dose of 100 mg/m2 on days 1 and 8.
A physical examination and an assessment of hematologic, hepatic, and
renal function were carried out at baseline and on the first day of each subse-
quent cycle in all treatment arms. All patients had hematologic function
measured again on day 1; patients in arm A (gemcitabine/cisplatin) or arm B
(fixed dose rate gemcitabine) had hematologic function also measured on day
15. Renal function was repeated on day 15 for patients receiving gemcitabine/
cisplatin. Dose reductions were instituted for febrile neutropenia, hematologic
toxicity, pulmonary toxicity, neurotoxicity, or hepatic toxicity in all arms of the
study. Drug-specific dose modifications were also instituted for renal toxicity
(cisplatin), hypersensitivity reactions (docetaxel), or diarrhea (irinotecan). For
other nonhematologic toxicities, treatment was held until resolution and then
resumed at 75% of the previous dose of all drugs in the event of grade 2 or 3
toxicity or at 50% of the previous dose in the event of grade 4 toxicity.
Disease response was documented by computed tomography, which was
performed at baseline and every two cycles for patients in arms A and B or
every three cycles for patients in arms C and D. Tumor response was measured
according to Response Evaluation Criteria in Solid Tumors (RECIST); how-
ever, given the extensive fibrosis common in primary pancreatic tumors, only
metastatic tumor sites were considered measurable for response evaluation.
Patients evaluable for CA 19-9 response included those whose baseline CA
19-9 was elevated  75% from normal. A CA 19-9 response was defined as a
decrease of  75% sustained over two measurements at least 4 weeks apart.
Patients continued treatment until documented disease progression, unac-
ceptable toxicity, withdrawal of consent, or the investigator thought change in
therapy was in the best interest of the patient.
Statistical Plan
OS at 6 months was the primary efficacy end point of the study and was
measured from time of protocol registration to time of death from any cause.
Assuming a median OS of 6 months, with 60 patients in each arm, the
proportion of patients surviving 6 months could be estimated within, at most,
 0.11 month with 90% confidence in each arm. Estimation of the biomarker
CA 19-9 response was a secondary objective. Patients were additionally ob-
served for radiologic tumor response, time to disease progression, and toxicity.
Treatment arms were compared descriptively for efficacy and toxicity end
points. OS and TTP were estimated using the Kaplan-Meier method. TTP was
defined as the time from study entry until documented progression or death




A total of 259 patients were enrolled onto the study between
January 15, 2001 and December 12, 2003; the patient characteristics
are listed in Table 1. Of the patients enrolled, 245 were eligible and
received treatment. Patients were evenly distributed among the four
treatment arms with regard to age and performance status. The ma-
jority of patients in all four arms (56% to 68%) were male. Less than
20% of patients in each arm had received prior adjuvant chemother-
apy with fluorouracil or external-beam radiation. Thirty percent of
patients subsequently received second-line chemotherapy after treat-
ment on the study; the frequency of second-line therapy was similar in
the four arms.
Table 2. Selected Grade 3 or 4 Adverse Events, According to Treatment Arm
Adverse Event
Maximum Toxicity Grade (% of patients)
Arm A: Gemcitabine/
Cisplatin (n  62)
Arm B: FDR
Gemcitabine (n  58)
Arm C: Gemcitabine/
Docetaxel (n  65)
Arm D: Gemcitabine/
Irinotecan (n  60)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Hematologic toxicity
Neutrophils 27 19 26 22 18 14 18 7
Leukocytes 32 6 21 16 18 9 13 7
Platelets 47 2 22 3 9 0 12 2
Hemoglobin 13 3 12 0 14 2 5 0
Nonhematologic toxicity
Fatigue 11 5 12 2 18 3 17 2
Hyperglycemia 6 3 7 2 32 2 8 2
Nausea 23 0 12 0 9 0 15 0
Vomiting 18 0 12 2 8 0 10 0
Dehydration 5 0 5 0 8 0 10 0
Diarrhea 0 0 2 0 6 2 18 0
Infection 6 0 4 2 13 0 3 0
Alkaline phosphatase 6 0 3 0 8 0 8 0
Anorexia 3 2 5 0 8 0 0 0
Dyspnea 0 0 2 0 9 0 3 2
Thrombosis 0 3 0 0 5 5 3 0
Bilirubin 2 0 2 2 2 0 3 0
Febrile neutropenia 2 0 3 0 5 0 2 0
Edema 3 0 2 0 2 0 3 2
GI bleeding 0 0 0 0 3 2 0 0
NOTE. Grade 3 or 4 adverse events experienced by two or more patients in any arm are listed. Grade 5 (fatal) toxicities included: arm A, renal failure (n  2); arm
B, infection (n  1) and seizure (n  1); and arm D, infection (n  1).
Abbreviation: FDR, fixed dose rate.
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Study Treatment
The median length of time that patients remained on study
treatment varied from 6.1 weeks (fixed dose rate gemcitabine) to 12.1
weeks (gemcitabine/irinotecan). Dose modifications or delays for tox-
icity were common and occurred in nearly all of the patients (94%)
receiving gemcitabine/cisplatin, 83% of patients receiving gemcitab-
ine/irinotecan, 78% of patients receiving fixed dose rate gemcitabine,
and 71% of patients receiving gemcitabine/docetaxel.
Neutropenia was the most common significant hematologic
toxicity, and fatigue was the most common nonhematologic tox-
icity; both occurred at a similar incidence in all four treatment
arms (Table 2). Other toxicities seemed to be more treatment arm
dependent and reflected known adverse effects of the regimens
used. Thrombocytopenia, nausea, and vomiting were most pro-
nounced in patients receiving gemcitabine/cisplatin, whereas diar-
rhea occurred almost exclusively in patients receiving gemcitabine/
irinotecan. Grade 3 or 4 hyperglycemia developed in 34% of
patients receiving gemcitabine and docetaxel and was likely related
to pretreatment with corticosteroids.
Overall, 19% of the patients withdrew from the study as a
result of adverse events; the rate of withdrawal as a result of adverse
events was similar in the four treatment arms (Table 3). A total of
21 patients died while receiving study treatment. Of these, five pa-
tients were classified as having experienced grade 5 (fatal) toxicities.
Two patients receiving gemcitabine/cisplatin died of treatment-
induced renal failure. Two patients died of treatment-related infec-
tions (one receiving fixed dose rate gemcitabine and one receiving
gemcitabine/irinotecan), and one patient receiving fixed dose rate
gemcitabine experienced a fatal seizure.
Efficacy
Six-month survival, the primary end point, was similar in all four
treatment arms and ranged from 53% (gemcitabine/cisplatin) to 57%
(fixed dose rate gemcitabine and gemcitabine/irinotecan; Table 4). OS
was also similar in all four treatment arms (Table 4; Fig 1A). The
median OS ranged from 6.4 months (fixed dose rate gemcitabine) to
7.1 months (gemcitabine/irinotecan). The median TTP ranged from
Table 3. Reason for Treatment Discontinuation




























Progressive disease 38 61 32 55 39 60 33 55 142 58
Adverse event 13 21 9 16 12 18 12 20 46 19
Death 3 5 6 10 7 11 5 8 21 9
Withdrew from study 7 11 9 16 7 11 6 10 29 12
Other 1 2 2 4 0 4 7 7 3
Abbreviation: FDR, fixed dose rate.
Table 4. Efficacy Results According to Treatment Arm
Efficacy
Arm A: Gemcitabine/
Cisplatin (n  56)
Arm B: FDR
Gemcitabine (n  43)
Arm C: Gemcitabine/
Docetaxel (n  57)
Arm D: Gemcitabine/










Complete response 1 2 0 0 1 2
Partial response 6 11 6 14 7 12 6 12
Stable disease 30 54 25 58 30 53 28 55
Progressive disease 19 34 12 28 20 35 16 31
CA 19-9 response 15/46† 33 16/38 42 19/48 42 16/48 33
Time to tumor progression, months
Median 4.5 3.3 4.1 4.0
95% CI 2.6 to 5.5 2.7 to 4.6 2.4 to 4.9 2.5 to 5.2
Patients alive at 6 months 33 53 33 57 35 54 34 57
Overall survival, months
Median 6.7 6.4 6.4 7.1
95% CI 5.0 to 7.8 4.4 to 9.9 5.1 to 7.9 5.4 to 8.8
Abbreviations: FDR, fixed dose rate; RECIST, Response Evaluation Criteria in Solid Tumors.
Confirmed.
†No. of patients/total No. of patients.
Gemcitabine-Based Combinations in Pancreatic Cancer
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3.3 months (fixed dose rate gemcitabine) to 4.5 months (gemcitabine/
cisplatin; Table 4; Fig 1B).
Radiologic and biochemical (CA 19-9) responses were secondary
end points of our study. The number of patients evaluable for these
end points was less than the number evaluable for survival as a result of
the definitions of response used for the study (Table 4). One of the
clinical characteristics of pancreatic cancer is extensive desmoplasia
around the primary tumor, making it difficult to assess response or
progression of disease at this site using standard imaging criteria. For
the purposes of this study, therefore, we elected to consider only
metastatic sites measurable for response. Confirmed radiologic re-
sponse rates were indistinguishable among treatment arms and
ranged from 12% (gemcitabine/docetaxel) to 14% (fixed dose rate
gemcitabine and gemcitabine/irinotecan). CA 19-9 response rates
were also similar between treatment arms and ranged from 33%
(gemcitabine/cisplatin and gemcitabine/irinotecan) to 42% (fixed
dose rate gemcitabine).
DISCUSSION
This multi-institutional, randomized, phase II study showed that four
gemcitabine-based regimens (gemcitabine/cisplatin, fixed dose rate
gemcitabine, gemcitabine/docetaxel, and gemcitabine/irinotecan) re-
sult in similar response and survival times in patients with advanced
pancreatic cancer. Objective tumor response rates associated with the
four regimens were within the narrow range of 12% to 14%. Median
OS times were also similar and ranged from 6.4 to 7.1 months. Toxic-
ities, although not prohibitive, were apparent in all four arms and were
consistent with the anticipated effects of the four regimens. Conse-
quently, we concluded that none of these regimens merited further
assessment in a phase III study.
After the completion of this study, three of the four regimens we
evaluated were directly compared with standard gemcitabine in ran-
domized phase III trials performed by other groups. The combination
of gemcitabine and cisplatin was evaluated in a German multicenter
randomized trial comprising 195 patients, of whom 20% had locally
advanced disease and 80% had metastatic disease.14 The treatment
regimen used in that study (cisplatin 50 mg/m2 on days 1 and 15 and
gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28-day cycle) was
identical to that used in our study. As in our study, nausea and
vomiting, presumably secondary to the incorporation of cisplatin,
were common. Tumor response rates were similar in the cisplatin/
gemcitabine and gemcitabine alone arms (10.2% v 8.2%, respec-
tively). Although both the reported progression-free and median
survival times associated with the combination arm were longer than
those associated with standard gemcitabine, the median survival dif-
ference did not reach statistical significance.
Fixed dose rate gemcitabine, which comprised the second arm of
our study, was first compared with gemcitabine administered as a
standard infusion in a randomized phase II study and, subsequently,
with standard gemcitabine or fixed dose rate gemcitabine/oxaliplatin
in an 833-patient, three-arm, randomized phase III study performed
by the ECOG (ECOG 6201).12,15 The randomized phase II study
compared gemcitabine 1,500 mg/m2 administered at a fixed dose rate
of 10 mg/m2/min (the regimen used in our study) with a standard
30-minute infusion of high-dose gemcitabine (2,200 mg/m2).12 The
median survival time was 8 months in the fixed dose rate arm com-
pared with only 5 months in the standard infusion arm (P  .013). In
the subsequent phase III study (ECOG 6201), a small improvement in
survival was observed with fixed dose rate gemcitabine, although this
did not meet the threshold set for statistical significance.15
Two randomized trials have compared gemcitabine and irinote-
can with standard gemcitabine. In the first study, which used the same
gemcitabine/irinotecan regimen that was part of our study, the com-
bination arm, compared with standard gemcitabine, was associated
with a higher tumor response rate (16.1% v 4.4%, respectively) but no
difference in OS (6.3 v 6.6 months, respectively).16 The incidence of
grade 3 or 4 diarrhea in patients receiving irinotecan in this study was
18.5%, which is identical to the 18% incidence observed in arm D of
our study. A second randomized study comprising 145 patients used a
different combination regimen, in which standard gemcitabine was
compared with gemcitabine administered at a dose of 900 mg/m2
weekly for 3 out of 4 weeks combined with irinotecan 300 mg/m2 on
day 8.17 Combination therapy was again associated with a higher
response rate compared with standard gemcitabine (15% v 10%, re-
spectively), but there were no significant differences in TTP or me-
dian survival.
Survival durations associated with other combinations have also
been either equivalent or only marginally superior to those associated
with single-agent gemcitabine in randomized studies. The median
survival time associated with gemcitabine/pemetrexed was 6.2
months, compared with 6.3 months with single-agent gemcitabine, in









10 20 30 40 50




















10 20 30 40






















Fig 1. (A) Overall survival and (B) time to progression according to treatment
arm. Gem, gemcitabine; Cis, cisplatin; Doc, docetaxel; Iri, irinotecan.
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the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
and Italian Group for the Study of Gastrointestinal Tract Cancer
(GISCAD) compared standard gemcitabine with a regimen of fixed
dose rate gemcitabine administered in combination with oxalipla-
tin.19 This study reported an improvement in progression-free
survival associated with the combination regimen but failed to dem-
onstrate a significant OS difference.
One potential difficulty in comparing results across studies of
novel regimens in pancreatic cancer has been the variable inclusion of
patients with locally advanced and metastatic disease. To minimize
patient heterogeneity in our study, we included only patients with
metastatic disease. The median survival times associated with combi-
nation chemotherapy in our study, which ranged from 6.4 to 7.1
months, match closely with the median survival time reported for
patients with metastatic disease receiving single-agent gemcitabine
(6.7 months) in the GERCOR/GISCAD trial. This finding is consistent
with our interpretation that none of the four regimens evaluated in
our study is likely to offer a significant improvement over treatment
with gemcitabine alone.
To date, only two gemcitabine-based regimens—gemcitabine/
erlotinib and, in a preliminary report, gemcitabine/capecitabine—
have been associated with statistically significant improvements in OS
when compared directly with gemcitabine alone in the randomized
setting.3,4 In both of these two studies, the survival benefit was rela-
tively small and was achieved at a cost of increased toxicity. Both
the gemcitabine/capecitabine and gemcitabine/erlotinib randomized
studies included more than 500 patients and were thus powered to
detect small survival differences. Several meta-analyses have, in fact,
suggested a benefit associated with combination chemotherapy.20,21
The largest of these studies evaluated 9,970 patients from 51 random-
ized trials and reported a statistically significant survival advantage
associated with gemcitabine combination therapy compared with
gemcitabine alone (hazard ratio  0.91; 95% CI, 0.85 to 0.97).22
Whether this difference is clinically meaningful remains unclear, par-
ticularly in light of the enhanced toxicity associated with many com-
bination regimens.
In conclusion, we observed similar efficacy associated with four
gemcitabine-based regimens in patients with metastatic pancreatic
adenocarcinoma. These findings do not support the further study of
any of these regimens in this setting. Our study demonstrates the
feasibility of evaluating four potentially promising regimens in a ran-
domized fashion in this disease. The observed results are consistent
with subsequent phase III studies in advanced pancreatic cancer and
suggest that adopting a similar approach to evaluate future agents in
pancreatic cancer may be an efficient way to rapidly assess which
regimens to bring forward in phase III randomized studies.
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